Page 147 - CW E-Magazine (9-1-2024)

Pharmaceuticals Pharmaceuticals

PHARMA EXHIBITION TAKING STOCK
Over 48,000 visitors attend CPHI & PMEC India 2023 Investments worth around Rs. 26,000-crore made

under pharma PLI till Sept. 2023: Govt.
Over 48,000 visitors from around
120 countries and close to 1,500 exhi- Investments worth Rs. 25,813-crore under three categories for a period outlay of Rs. 3,420-crore, a total 64
bitors participated in the CPHI & PMEC have been made and 56,171 new jobs of six years. One of the categories is applications across four categories of
India 2023 trade show held at Greater were added as of September 2023 API manufacturing. The investment products were received and 26 applica-
Noida, Delhi-NCR between November under the production-linked incentive committed by the selected applicants tions approved with committed invest-
28-30, 2023, according to a press note (PLI) scheme for pharmaceuticals, the was Rs. 17,275-crore, against which ment of Rs. 1,330.44-crore. As of Sep-
from the organiser, Informa Markets.
government has informed. investment worth Rs. 25,813-crore tember 2023, out of the 26 approved
has already been realised. projects, 16 have been commissioned
Touted as the “largest pharmaceuti-
and manufacturing of 39 medical devices
In its year-end review, the Depart-
cal industry gathering in South Asia”, ment of Pharmaceuticals (DoP) also For the PLI scheme for promotion has started.
the exhibition spread over 100,000-m 2 said the ‘Pradhan Mantri Bhartiya of domestic manufacturing of critical
featured domestic powerhouses like Janaushadhi Pariyojana’ achieved its key starting materials (KSMs), drug For the scheme for promotion of
Dr. Reddy’s and Biocon and global lead-
target of opening 10,000 retail outlets in intermediates (DIs) and active pharma- bulk drug parks, with a fi nancial out-
2023 to provide quality generic medi- ceutical ingredients (APIs) with a lay of Rs. 3,000-crore and the tenure
cines at affordable prices to the poor fi nancial outlay of Rs. 6,940-crore and from FY21 to FY25, DoP received
and underprivileged. tenure from FY21 to FY30, DoP said a proposals from 13 States. After evalu-
total of 249 applications across all four ation of the proposals as per prescribed
The PLI scheme for pharmaceuti- categories of products were received. criteria, the approval was accorded to
cals is being implemented with an These bulk drugs/APIs are in addition Andhra Pradesh, Gujarat and Himachal
objective of enhancing India’s manu- to the APIs manufactured under PLI Pradesh.
facturing capabilities by increasing scheme for pharmaceuticals. Out of
investment and production in the sector the 249 applications, 48 have been ap- FDI infl ows in the pharmaceutical
ers like IMA and Fette, alongside rising and contributing to product diversifi ca- proved with committed investment of sector (comprising both pharmaceuti-
stars like Piramal Pharma and Hetero tion to high value goods in the pharma- Rs. 3,938.57-crore, the statement added. cals and medical devices) between
Labs, showcasing cutting-edge pro- ceutical sector. As of September 2023, out of 48 April 2023 to September 2023, stood
ducts ranging from AI-enhanced qua- approved projects, 27 projects have at Rs. 4,456-crore. Further, the DoP
lity control to pioneering drug delivery The total outlay of the scheme of been commissioned. has approved six FDI proposals worth
systems and sustainable initiatives. The Rs. 15,000-crore will provide fi nancial Rs. 9,848-crore for brownfi eld projects
16th edition of the event also hosted incentive to 55 selected applicants Similarly, for the PLI scheme for during April 1, 2023 to November 30,
over 25,000 buyer-seller meetings, for production of identifi ed products medical devices, which has a fi nancial 2023, it said.
fostering partnerships. BDR Pharma introduces prostate cancer treatment

The key highlight of the event was transformation to optimise operations nearly 30% of Indians lacking access to drug in oral solution form
the ‘India Pharma Week’ – a curated and curtail expenses, besides the need medicines. We are truly at an infl ection
series of events including the Pharma for innovation funding through strategic point where we are fi nding innovative BDR Pharmaceuticals said it has a signifi cant step forward in providing lots of pills,” BDR Pharmaceuti-
Leaders Golf; Pre-Connect Congress; alliances and the establishment of inno- ways for seamless geographical dis- introduced Enzalutamide oral solution an effective dosage form with lesser cals Director, Technical Formulation,
Pharma Leaders Roundtable; Women vation clusters. tribution of pharmaceutical access of for treatment of prostate cancer, claiming side effects in comparison to existing Mr. Aravind Badiger, said.
in Pharma; Pharma Talks; and India quality supply. For 16 years, CPHI & to be the fi rst company in the world to oral dosage forms of Enzalutamide, it
Pharma Awards. Highlighting India’s promising PMEC India has been at the pulse of bring it through the new drug delivery added. Unlike fi xed-dose tablets, doctors
position within the global market, the pharma industry’s meteoric rise, system. The company has introduced the can adjust the dosage to fi t each patient
A closed-door ‘Pharma Leaders’ Mr. Yogesh Mudras, Managing Direc- evolving from a trade show to a global Enzalutamide oral solution as BDENZA, “Changing how we treat prostate better. This oral solution is gentle on
Roundtable’ underscored the critical tor, Informa Markets in India said, hub for innovation and collaboration. in 32 mg/ml priced at Rs. 27,000 for cancer, BDENZA oral solution brings the stomach, avoiding issues like nau-
importance of directing attention “India has earned its way to becoming We proudly represent the world’s larg- 150ml, BDR Pharmaceuticals said in a mix of benefi ts to make things better sea. It is a more patient-friendly way
towards both incremental and revolu- a pharma super power with over 200+ est pharma community, fuelling India’s a statement. for patients. It gives a strong 160-mg to tackle prostate cancer and can help
tionary innovation. Speakers debated countries served by Indian pharma domestic muscle, surging R&D, and dose in just one small 5-ml serving, improve patient compliance to a great
topics like cost effi ciency and digital exports. And yet, obstacles remain with government support”. This innovative formulation marks so there’s less hassle associated with extent, Mr. Badiger said.

146 Chemical Weekly January 9, 2024 Chemical Weekly January 9, 2024 147

Contents Index to Advertisers Index to Products Advertised